Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) disclosed that Marion McCourt, the company's Executive Vice President Commercial, sold 566 shares of common stock on November 16, 2026, according to a regulatory filing. The shares were sold at prices ranging from $952.79 to $971.93, resulting in a total transaction value of $543,504.
The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, which McCourt adopted on February 17, 2026. Such plans allow company insiders to set up predetermined schedules for buying or selling stock, providing a defense against allegations of trading on material nonpublic information.
Following the transaction, McCourt directly holds 10,305 shares of Regeneron common stock. In addition, she indirectly holds 219 shares through a 401(k) plan.
The sale occurred as Regeneron shares trade near their 52-week high of $991.73. The stock has gained 44% over the past six months. According to an analysis, the stock remains undervalued, with shares recently trading at $920.69 and the company carrying a market valuation of $92.66 billion.
In other recent developments, Regeneron reported significant progress in its financial and product portfolio. Dupixent, the company's leading revenue-generating product, saw a 35% increase in sales during the third quarter of 2026, reaching $6.54 billion. This strong performance led Argus to raise its price target for Regeneron shares to $1,050 while maintaining a Buy rating. Cantor Fitzgerald also increased its price target to $980, highlighting Dupixent's contribution to Sanofi collaboration revenue, which reached $2.72 billion.
Additionally, Regeneron received FDA approval for Livsayis (cemdisiran) for treating generalized myasthenia gravis. This approval prompted Truist Securities to reiterate a Buy rating with a $982 price target. TD Cowen maintained its Buy rating and $980 price target following the approval, emphasizing the treatment's REMS and vaccination requirements. Meanwhile, Jefferies reiterated a Buy rating with a $1,065 price target in anticipation of a Patent Trial and Appeal Board hearing on Regeneron's EYLEA HD '036 patent, which could extend protection until 2039.
These developments reflect the company's robust performance and strategic advancements in its product offerings.